RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

Clinical trials for RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Race to control returning blood cancer: two drug duos face off in major trial

Disease control Recruiting now

This study is testing which of two different drug combinations works better for people whose marginal zone lymphoma has returned or stopped responding to previous treatment. Researchers will compare orelabrutinib plus rituximab against lenalidomide plus rituximab in 324 participa…

Matched conditions: RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

Phase: PHASE3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control

Last updated Mar 23, 2026 15:16 UTC

RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

Get alerted when new RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA trials appear

Race to control returning blood cancer: two drug duos face off in major trial